All News
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group
@RheumNow https://t.co/iucDK1GpU4
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf
Richard Conway RichardPAConway ( View Tweet)
Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared to 2nd TNFi following failure of 1st TNFi. @RheumNow #ACR22 Abstr#2149 https://t.co/Er2FKwYdRv https://t.co/uMPSfMkjfa
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp
Richard Conway RichardPAConway ( View Tweet)
Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs
Richard Conway RichardPAConway ( View Tweet)
Black et al. Treat to target in gout. Monthly rheumatologist review and urate titration vs 6-monthly. 89% vs 40% at target ≤0.30mmol/L (<5mg/dl). SU decrease 38% vs 18%. US features also improved. @RheumNow #ACR22 Abstr#1579 https://t.co/TvxWAtl83y
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk
@RheumNow #ACRBest https://t.co/swYn2g4hqe
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SLE mortality in South Carolina Lupus Cohort
Standardized mortality ratio (SMR) is higher in blacks
Higher SLICC scores in blacks
abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc
Bella Mehta bella_mehta ( View Tweet)
Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU
Richard Conway RichardPAConway ( View Tweet)
Hoffmann-Vold. ILD in pSS. Frequently progressive - 21% FVC, 32% DLCO, 45% HRCT progression over 1 year. @RheumNow #ACR22 Abstr#2049 https://t.co/um3845jOFC https://t.co/64BEB2VyG0
Richard Conway RichardPAConway ( View Tweet)
New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML
Janet Pope Janetbirdope ( View Tweet)
Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L
Richard Conway RichardPAConway ( View Tweet)
Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5
Janet Pope Janetbirdope ( View Tweet)
⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas involved in sensory (thalamus), learning/affective (parahippocampal gyrus), cognitive (prefrontal cortex) pain modulation in PsA. Sunzini F Abs#2256 https://t.co/5TUcOacuIS #ACR22 @RheumNow https://t.co/7IqLYzzpyA
Dr. Antoni Chan synovialjoints ( View Tweet)
Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz
Richard Conway RichardPAConway ( View Tweet)
Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8
Richard Conway RichardPAConway ( View Tweet)
Rhee @RennieRhee et al. Combined cranial vessel wall and orbital MRI for GCA. Improves sensitivity 77% vs 69% with loss of specificity 91% vs 95%. Identifies abnormalities in some without visual symptoms - at risk of vision loss @RheumNow #ACR22 Abstr#1618 https://t.co/OtGm7sEWtU https://t.co/YM4WLahubH
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)